AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01427660 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Health Worker Diabetes Education: Print media
Description: Providing information to patients about potential benefits, harms, costs, and burdens of medications and discussing patients' treatment preferences.
Study NCT01427660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW Diabetes Education: tailored web site
Description: Providing tailored and interactive information to patients about potential benefits, harms, costs, and burdens of medications and discussing patients' treatment preferences.
Study NCT04490265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-solving treatment
Description: included in arm descriptions
Study NCT04490265 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supportive Psychotherapy
Description: included in arm descriptions
Study NCT01720693 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoperfusion of renal artery
Description: The renal artery is occluded to 30% of it's baseline, prior to kidney tumour removal
Study NCT03425695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical examination
Description: The shrinkage of the graft area was calculated according to the differences between the graft area at baseline, 1st, 3rd, and 6th months.~Epithelization was determined via bubbling test by using 3% hydrogen peroxide (H2O2) at 7, 14, 21, and 28 days after surgery.
Study NCT04497948 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acalabrutinib
Description: Acalabrutinib (CALQUENCE®) is a covalent BTK inhibitor
Study NCT00866658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
Study NCT00866658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
Study NCT00866658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector
Study NCT00866658 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pen auto-injector
Study NCT00866658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Description: Sulfonylurea if given, to be continued at a stable dose.
Study NCT02839044 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Menaquinone-7
Study NCT02839044 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00940849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant sterol containing drink
Description: The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
Study NCT00940849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard macaroni meal
Description: The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
Study NCT02766972 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid Ventricular Pacing
Description: Use of Rapid Ventricular Pacing to improve surgical clipping of intracranial aneurysms
Study NCT02410590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Study NCT02410590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Study NCT00866658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulfonylurea
Description: Sulfonylurea if given, to be continued at a stable dose.
Study NCT00866658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal Insulin
Description: To be continued at a stable dose.
Study NCT00866658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Basal Insulin
Description: To be continued at a stable dose.
Study NCT03058094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed will be administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle. Folic acid will be administered 1-2 weeks prior to the 1st dose, then daily during the treatment period until 21days post the last dose. Vitamin B12 will be administered on the same day of pemetrexed infusion during the treatment period. Corticosteroid will be adminstered on the day prior to, on the day, and on the day after infusion.
Study NCT03058094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin 75mg/m2
Description: Cisplatin will be administered as an intravenous infusion.
Study NCT03058094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC0010
Description: 300mg, orally, BID
Study NCT02410590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisatracurium
Study NCT02410590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine/Atropine
Study NCT02138058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Study NCT02138058 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive restructuring intervention
Description: 4 sessions of a manualized cognitive restructuring intervention for compulsive buying
Study NCT02138058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring intervention
Description: 4 sessions of a manualized cognitive restructuring intervention for compulsive buying
Study NCT03361930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle-foot orthosis
Description: Two custom ankle-foot orthoses for the involved lower leg; cast, rectified and fitted by same certified orthotist to reduce clinician variability.~The cast is rectified according to the specifications of Hylton (1987) to produce tone-reducing features in the foot plate; the tone-reducing ankle-foot orthosis is manufactured on this cast. The orthotist then remodels the cast with a flat foot plate; the plain ankle-foot orthosis is then manufactured.
Study NCT00244478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Protein Dietary Supplement
Description: The soy-based meal replacements will contain 20 g soy protein and 161.2 mg isoflavones, 220-240 kcal, 31-36 g total carbohydrates, 0-2 g dietary fiber, 500 mg calcium, and 2.0-2.5 g total fat per serving.
Study NCT00244478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control shake will have 20 g casein substituted for soy protein, and will be otherwise identical to the soy shakes. The shakes will be available in two flavors: chocolate and vanilla.
Study NCT04260971 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abbott St Jude Medical Infinity 7 neurostimulator
Description: The stimulator has the capability to deliver both continuous and cyclical modes of stimulation which is being investigated in this study
Study NCT04260971 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott St Jude Medical Infinity 7 neurostimulator
Description: The stimulator has the capability to deliver both continuous and cyclical modes of stimulation which is being investigated in this study
Study NCT02787408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EW Tricuspid Transcatheter Repair System
Description: Treatment with the EW Tricuspid Transcatheter Repair System
Study NCT06548308 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Corneal Incision
Description: Astigmatism will be assessed by objective and subjective refraction by using the Autorefrectometer and retinoscop.Autorefrectometer uses to acsess the refracive state of eye by which we measure the astigmatim in patients eyes .Then after ctaract surgry in the next followup we will again use autorefrectometer to take readings and these both will be compared on visits among patients undergoing two procedures.
Study NCT06548308 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toric Intraocular
Description: Two cataract surgery techniques will be used .1 : Toric IOL lenses designed with a unique shape to help provide clear vision at all distances for individuals with astigmatism compared to give better results specially in astigmatic patients.2: Corneal Inscion is which eye surgeon makes a very small opening on the eye, next to the outer corner. to remove the catract during surgry .
Study NCT04156958 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fruquintinib
Description: Fruquintinib will be administered orally at a dose of 5 mg/d, 3 weeks on, 1 week off (4 weeks as a cycle) until progression, unacceptable toxicity, or withdrawal unless toxicity not relieved after dose adjustment.
Study NCT03613727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) and oral Vitamin C
Description: Intravenous (IV) vitamin C 50 mg/kg/day divided in 3 doses beginning on posttransplant Day +1 and continuing through Day +14; each dose (16.7 mg/kg) given in 50 mL of 5% dextrose and water over 30 minutes every 8 hours~• After completion of the IV vitamin C doses, oral vitamin C 500 mg twice each day beginning on Day +15 and continuing until Day +180
Study NCT01922804 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: K2 vitamin
Description: K2 vitamin tablet
Study NCT02410590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Succinylcholine
Study NCT04185662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sucralose
Description: daily intake different dose of artificial sweeteners sucralose or placebo
Study NCT04185662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sucralose
Description: daily intake different dose of artificial sweeteners sucralose or placebo
Study NCT00790218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF102
Description: CF102 capsules twice daily by mouth
Study NCT02412527 — intervention group
Intervention type: OTHER
Intervention: Patch III heart rate sensor
Study NCT02124928 — intervention group
Intervention type: PROCEDURE
Intervention: Carotid endarterectomy
Description: Carotid endarterectomy is a surgery used to reduce the risk of stroke, by correcting stenosis in the carotid artery. Endarterectomy is the removal of material on the inside (end-) of an artery.An incision is made on the midline side of the Sternocleidomastoid muscle. The incision is between 5 and 10 cm in length. Then the patients get 5000 IU heparin by the anesthesia. The internal, common and external carotid arteries are carefully identified, controlled with vessel loops, and clamped. The lumen of the internal carotid artery is opened, and the atheromatous plaque removed. The artery is closed using suture. The procedure is performed under local anesthesia. Local anesthesia, opposite to general, allows for direct monitoring of neurological status by intra-operative verbal contact and testing of grip strength.
Study NCT03138291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somnodent
Description: Each pregnant women will be treat with a Somnodent
Study NCT01378091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Supplied as 5 mg and 25 mg capsules.~The lenalidomide dose levels to be studied include 10, 15, 20, 25, 30, 35 and 40 mg/day.
Study NCT01378091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug.~Doses of docetaxel to be studied include 60 and 75 mg/m2 once every three weeks.
Study NCT01378091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone is a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug.~5 mg BID daily.
Study NCT02703649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: After the decision to use Letrozole for induction of ovulation, we will obtain informed consent and randomize the patents into 2 groups Single 20 mg dose of Letrozole on day 3 of the cycle Daily dose of Letrozole 2.5 mg starting day 3 for 5 days.
Study NCT02703649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: After the decision to use Letrozole for induction of ovulation, we will obtain informed consent and randomize the patents into 2 groups Single 20 mg dose of Letrozole on day 3 of the cycle Daily dose of Letrozole 2.5 mg starting day 3 for 5 days.
Study NCT02596425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 40 cmH2O
Description: The intervention was five manual inflations of the lungs with positive pressure ventilation of 40 cmH2O at the end of surgery.
Study NCT02596425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 60 cmH2O
Description: The intervention was five manual inflations of the lungs with positive pressure ventilation of 60 cmH2O at the end of surgery.
Study NCT02596425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive deflation
Description: In the controls, CO2 was removed by the traditional passive deflation of abdominal cavity.
Study NCT01922804 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT04234932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil Ophthalmic
Description: Topical instillation of commercial preparations of netarsudil 0.02% ophthalmic solution (Rhopressa and Roclatan)
Study NCT04234932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Netarsudil Ophthalmic
Description: Topical instillation of commercial preparations of netarsudil 0.02% ophthalmic solution (Rhopressa and Roclatan)
Study NCT04634318 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory rehabilitation program (RR).
Description: Patients in the RR group will follow the respiratory rehabilitation program during a 4-week hospitalization in the respiratory diseases department of Renée Sabran hospital (Hyères, France).~The program includes for each week:~One medical consultation Four 40-min sessions of aerobic exercises on an ergocycle Four 1-hour sessions of walking in Renée Sabran Hospital's park Three 1-hour sessions of muscle strengthening exercises One 1-hour session of sophrology One 1-hour session of occupational therapy One 1-hour session of psychomotricity
Study NCT04634318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory tele-rehabilitation program (TRR).
Description: Patients in the TRR group will realize the 4-week respiratory tele-rehabilitation program at home. The TRR program for each week includes the same sessions as RR program. But, medical consultation, sophrology, occupational therapy, psychomotricity and muscle strengthening sessions are carried out through live videoconferences. Additionally, aerobic and walking sessions are carried out outside home. The intensity of each session will be controlled by heart rate monitor.
Study NCT01829867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sNN0031
Study NCT00728728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement: Pregnenolone
Description: Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial.
Study NCT00728728 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00732706 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sartorius Muscle Twitch
Description: Stimulation of the femoral nerve branch responsible for activating the Sartorius Muscle fascia with the lowest possible current.
Study NCT00732706 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Quadriceps Muscle Twitch
Description: Stimulation of the femoral nerve branch responsible for activating the Quadriceps Muscle fascia with the lowest possible current.
Study NCT02768389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Subjects receive Bevacizumab as standard of care
Study NCT02768389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Atkins Diet
Description: The modified Atkins diet (MAD) includes high fat, unlimited protein, and restricted carbohydrates (\< 20gm/day).
Study NCT03930667 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: clips
Study NCT03930667 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: knotting
Study NCT04808310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quantitative flow ratio
Description: Quantitative flow ratio (QFR) is a computer method that estimates the hemodynamic relevance of a coronary stenosis based on three-dimensional quantitative coronary angiography (3D QCA)
Study NCT04808310 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of angiographic severity of the stenosis
Description: The indication to coronary stent intervention will be based on angiography
Study NCT00798876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Subjects will be asked to take 10 grams of fish oil per day for 4 weeks.
Study NCT00090766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valganciclovir [Valcyte]
Description: po daily (dose based on body surface area and CrCL)
Study NCT00606294 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fluorine-18-labeled fluoro-misonidazole (18F-FMISO)
Study NCT00606294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FMISO PET scan
Study NCT00606294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT00606294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDG PET/CT scan
Study NCT00486512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol)
Study NCT00486512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)
Study NCT00486512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol)
Study NCT00486512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)
Study NCT00486512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Study NCT00486512 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Colonoscopy
Study NCT00988377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: whey protein 10-40 g
Study NCT00988377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water control
Description: Iso-volumetric (300 ml) water control (Crystal Springs, Canada)
Study NCT02697058 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX2398 + 5-FU/calcium levofolinate
Description: BAX2398 (a liposomal formulation of irinotecan) in combination with 5-FU/calcium levofolinate
Study NCT02697058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU/calcium levofolinate
Description: 5-FU/calcium levofolinate alone
Study NCT04336007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resistive Diathermy (INDIBA® Activ Ct9)
Description: Intervention is conducted using a 65-mm diameter Resistive (RES) electrode (movable), and a planar electrode was used as a return electrode on the abdomen. The electricity is administered in the following manner: cream was applied to the upper limbs existent area, and the electrical output is marked at 75% by moving the movable electrode and if not tolerated by the patient lowered until 35%, Therapy is conducted for 20 minutes, prior swimming time trials.
Study NCT04336007 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Resistive Diathermy OFF (INDIBA® Activ Ct9)
Description: Placebo is conducted using a 65-mm diameter RES electrode (movable), and a planar electrode was used as a return electrode on the abdomen. The electricity IS NOT administered, the cream was applied to the upper limbs existent area and moving the movable electrode, intervention is conducted for 20 minutes, prior to swimming time trials.
Study NCT04336007 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: This group will warm-up as they usually do in competitions, for later time trial measuring.
Study NCT00837239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1,000 mg/m2 once a week for 3 weeks then 1 week off (28 Day Cycle).
Study NCT00837239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HuaChanSu
Description: 20 mL/m2 for total 500 mL given as a 2 hour infusion, 5 days a week for 3 weeks then one week off (28 Day Cycle).
Study NCT00837239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 500 ml saline only administered as a 2 hour infusion by central line.
Study NCT01154322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pixi pediatric mask
Description: The study mask is designed for use with PAP therapy to treat OSA in pediatric patients aged 2-7 years. The study mask is designed to be used in the hospital and the home environment. The study subject will use the device for up to 30 days while participating in the study.